Applied Genetic Technologies Corp. (AGTC) Stock Price Down 4%
Applied Genetic Technologies Corp. (NASDAQ:AGTC)’s share price traded down 4% during mid-day trading on Wednesday . The stock traded as low as $12.63 and last traded at $12.78, with a volume of 125,174 shares changing hands. The stock had previously closed at $13.31.
Several equities analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $32.00 price target on shares of Applied Genetic Technologies Corp. in a research note on Tuesday, May 10th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Applied Genetic Technologies Corp. in a research note on Tuesday, May 10th. Zacks Investment Research lowered Applied Genetic Technologies Corp. from a “buy” rating to a “hold” rating in a research note on Thursday, May 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Applied Genetic Technologies Corp. in a research note on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $26.00.
The stock has a 50 day moving average of $14.95 and a 200 day moving average of $15.08. The firm’s market capitalization is $230.46 million.
A hedge fund recently raised its stake in Applied Genetic Technologies Corp. stock. Jennison Associates LLC increased its stake in Applied Genetic Technologies Corp. (NASDAQ:AGTC) by 0.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 677,610 shares of the company’s stock after buying an additional 3,248 shares during the period. Jennison Associates LLC owned about 3.76% of Applied Genetic Technologies Corp. worth $13,823,000 as of its most recent filing with the SEC.
Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.